Acrivon Therapeutics, Inc.’s ACRV share price has dipped by 11.25%, which has investors questioning if this is right time to ...

Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend ...

Schrödinger’s stock surged after the FDA's initiative to phase out animal testing, benefiting its computational drug ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 8.97%, which has investors questioning if this is right time to buy.

To address this challenge, our research will study how SG can be combined with a WEE1 inhibitor, a drug that targets a key protein involved in the DNA damage response. We believe this combination ...

Shanghai Frontiers Science Center for Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China State Key Laboratory of ...

Erectile dysfunction occurs when there is not enough blood flowing to the penis. Phosphodiesterase-5 inhibitors, such as horny goat weed and Viagra, widen the blood vessels, increasing blood flow to ...

SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 ...

SGLT2 inhibitors are medications designed to help manage blood sugar in people living with type 2 diabetes. Learn more about the different types, as well as the benefits and side effects.

Clinical trials employing small-molecule MDM2/p53 interaction inhibitors have demonstrated limited activity, underscoring an unmet need for a better approach to target MDM2. KT-253 is a highly potent ...

1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan. 2Department of Obstetrics and Gynecology, The First Affiliated Hospital of Harbin Medical ...

The ongoing ACESOT-1051 (A Multi-Center Evaluation of WEE1 Inhibitor in Patients with Advanced Solid Tumors, APR-1051) clinical trial is a Phase 1 trial evaluating single-agent APR-1051 in patients ...